The US Center for Medicare and Medicaid Innovation’s plan to reduce drug costs by giving Medicare Part D beneficiaries access to select generic drugs for up to $2 a month did not receive a warm reception from the generic industry, largely because it is seen as focusing on drugs that are already firmly entrenched and not incentivizing better coverage of newer follow-on products.
Key Takeaways
-
New information on Medicare’s $2 generic drug copay innovation center model did not excite the generic drug industry because the list is dominated by medicines that are already highly genericized.
-
More than 100 generic drugs are included in CMMI’s initial list for the model and feedback on the list and other aspects of the model may be submitted until 9 December
“If CMS were to implement this, it would apply only to a select list of older, largely commoditized generics,” the Association for Accessible Medicines told Pink Sheet. “Further, there is no incentive for plans to participate
